A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)
Phase of Trial: Phase III
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UCanADA
- Sponsors AbbVie
- 10 Jun 2017 Biomarkers information updated
- 05 Apr 2017 Planned End Date changed from 1 Sep 2019 to 1 Feb 2022.
- 05 Apr 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Feb 2022.